CD59 (Protectin) Monoclonal Antibody (OV9A2), PE, eBioscience™, Invitrogen™

Description

• Description: This OV9A2 monoclonal antibody reacts with human CD59, which is also known as Protectin
• This GPI-linked membrane glycoprotein shares structural homology with the murine Ly-6 superfamily
• CD59 is expressed on all human lymphocytes, monocytes, granulocytes, and erythrocytes
• This protein is also expressed on non-hematopoietic cells, including endothelial cells and neurons
• By binding the complement components C8 and C9, CD59 inhibits assembly of the membrane attack complex and cytolytic activity by complement
• CD59 interacts with CD2 to modulate T cell adhesion, and also plays a role in T cell activation
• Finally, altered expression of CD55 and CD59 on human peripheral blood cells has been observed in patients with systemic lupus erythematosus (SLE)
• Crossblocking studies indicate that the OV9A2 monoclonal antibody binds the same epitope as MEM-43
• Applications Reported: This OV9A2 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This OV9A2 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.125 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• CD59 (Protectin) is a small (18-20 kDa) GPI-anchored ubiquitously expressed inhibitor of the membrane attack complex (MAC)
• CD59 is the key regulator that preserves the autologous cells from terminal effector mechanism of the complement cascade
• CD59 also associates with C5b-8 complex and counteracts appropriate formation of cytolytic pore within the plasma membrane
• Further, CD59 is a low-affinity ligand of human CD2, causes T cell costimulation, and is involved in lymphocyte signal transduction
• CD59 is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation
• Mutations in this gene cause CD59 deficiency, a disease involving hemolytic anemia, thrombosis, and cerebral infarction
• Multiple alternatively spliced transcript variants of CD59 have been identified.